These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 24518562

  • 1. Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data.
    Trkulja V, Lalić Z, Nađ-Škegro S, Lebo A, Granić P, Lovrić M, Pasini J, Božina N.
    Ther Drug Monit; 2014 Aug; 36(4):456-64. PubMed ID: 24518562
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M.
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [Abstract] [Full Text] [Related]

  • 3. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
    Pawinski T, Luszczynska P, Durlik M, Majchrzak J, Baczkowska T, Chrzanowska M, Sobiak J, Glyda M, Kuriata-Kordek M, Kamińska D, Krajewska M, Klinger M.
    Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
    [Abstract] [Full Text] [Related]

  • 4. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 5. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
    Huang HF, Yao X, Chen Y, Xie WQ, Shen-Tu JZ, Chen JH.
    Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
    [Abstract] [Full Text] [Related]

  • 6. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
    Lam H, Jeffery J, Sitar DS, Aoki FY.
    Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
    [Abstract] [Full Text] [Related]

  • 7. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H, Felipe CR, Slade A, Schmouder RL, Medina Pestana JO.
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [Abstract] [Full Text] [Related]

  • 8. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
    Mardigyan V, Tchervenkov J, Metrakos P, Barkun J, Deschenes M, Cantarovich M.
    Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
    [Abstract] [Full Text] [Related]

  • 9. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 10. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.
    Aw MM, Brown NW, Itsuka T, Gonde CE, Adams JE, Heaton ND, Tredger JM, Mieli-Vergani G, Dhawan A.
    Liver Transpl; 2003 Apr; 9(4):383-8. PubMed ID: 12682891
    [Abstract] [Full Text] [Related]

  • 11. Development and validation of limited sampling strategies for tacrolimus and mycophenolate in steroid-free renal transplant regimens.
    Poulin E, Greanya ED, Partovi N, Shapiro RJ, Al-Khatib M, Ensom MH.
    Ther Drug Monit; 2011 Feb; 33(1):50-5. PubMed ID: 21157401
    [Abstract] [Full Text] [Related]

  • 12. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V, Giannetti N, Cecere R, Besner JG, Cantarovich M.
    J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
    [Abstract] [Full Text] [Related]

  • 13. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.
    Lloberas N, Torras J, Cruzado JM, Andreu F, Oppenheimer F, Sánchez-Plumed J, Gentil MÁ, Brunet M, Ekberg H, Grinyó JM, Spanish Pharmacogenetic Symphony Substudy Group.
    Nephrol Dial Transplant; 2011 Nov; 26(11):3784-93. PubMed ID: 21427078
    [Abstract] [Full Text] [Related]

  • 14. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [Abstract] [Full Text] [Related]

  • 15. Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients.
    Mandla R, Midtvedt K, Line PD, Hartmann A, Bergan S.
    Transpl Int; 2006 Jan; 19(1):44-53. PubMed ID: 16359376
    [Abstract] [Full Text] [Related]

  • 16. Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions.
    Božina N, Lalić Z, Nađ-Škegro S, Borić-Bilušić A, Božina T, Kaštelan Ž, Trkulja V.
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1129-1140. PubMed ID: 28624888
    [Abstract] [Full Text] [Related]

  • 17. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation.
    van Gelder T, Silva HT, de Fijter H, Budde K, Kuypers D, Mamelok RD, Armstrong VW, Oellerich M.
    Ther Drug Monit; 2011 Apr; 33(2):155-64. PubMed ID: 21383657
    [Abstract] [Full Text] [Related]

  • 18. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
    de Winter BC, Mathot RA, Sombogaard F, Neumann I, van Hest RM, Doorduijn JK, van Gelder T.
    Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
    [Abstract] [Full Text] [Related]

  • 19. Influence of renal graft function on mycophenolic acid pharmacokinetics during the early period after kidney transplant.
    Mohammadpur AH, Nazemian F, Abtahi B, Naghibi M.
    Exp Clin Transplant; 2008 Dec; 6(4):276-81. PubMed ID: 19338489
    [Abstract] [Full Text] [Related]

  • 20. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.
    Tredger JM, Brown NW, Adams J, Gonde CE, Dhawan A, Rela M, Heaton N.
    Liver Transpl; 2004 Apr; 10(4):492-502. PubMed ID: 15048791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.